MCID: CCC001
MIFTS: 61

Coccidioidomycosis

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Coccidioidomycosis

MalaCards integrated aliases for Coccidioidomycosis:

Name: Coccidioidomycosis 12 77 54 60 56 3 45 15 17 74
Valley Fever 54 60 44 3
Primary Extrapulmonary Coccidioidomycosis 12 74
Coccidiosis 54 74
Primary Pulmonary Coccidioidomycosis 74
Coccidioides Immitis Infection 54
San Joaquin Valley Fever 60
Acute Coccidioidomycosis 74
Coccidioides Infection 60
Enteric Coccidiosis 74
California Disease 60
San Joaquin Fever 54
Desert Rheumatism 60
Desert Fever 60

Characteristics:

Orphanet epidemiological data:

60
coccidioidomycosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 60  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:13450
ICD9CM 36 114 114.9
MeSH 45 D003047
NCIt 51 C84642
SNOMED-CT 69 60826002
ICD10 34 B38 B38.9
MESH via Orphanet 46 D003047
UMLS via Orphanet 75 C0009186 C0153257 C0851907
Orphanet 60 ORPHA228123

Summaries for Coccidioidomycosis

MedlinePlus : 44 Valley Fever is a disease caused by a fungus (or mold) called Coccidioides. The fungi live in the soil of dry areas like the southwestern U.S. You get it from inhaling the spores of the fungus. The infection cannot spread from person to person. Anyone can get Valley Fever. But it's most common among older adults, especially those 60 and older. People who have recently moved to an area where it occurs are at highest risk for infection. Other people at higher risk include Workers in jobs that expose them to soil dust. These include construction workers, agricultural workers, and military forces doing field training. African Americans and Asians Women in their third trimester of pregnancy People with weak immune systems Valley Fever is often mild, with no symptoms. If you have symptoms, they may include a flu-like illness, with fever, cough, headache, rash, and muscle aches. Most people get better within several weeks or months. A small number of people may develop a chronic lung or widespread infection. Valley Fever is diagnosed by testing your blood, other body fluids, or tissues. Many people with the acute infection get better without treatment. In some cases, doctors may prescribe antifungal drugs for acute infections. Severe infections require antifungal drugs. Centers for Disease Control and Prevention

MalaCards based summary : Coccidioidomycosis, also known as valley fever, is related to cryptococcosis and q fever, and has symptoms including arthritis, chest pain and conjunctivitis. An important gene associated with Coccidioidomycosis is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Valproic Acid and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A primary systemic mycosis that results in systemic fungal infection, has material basis in Coccidioides immitis, transmitted by airborne spores and has symptom conjunctivitis, has symptom arthritis, has symptom chest pain and results in_formation_of skin nodules.

CDC : 3 Valley fever, also called coccidioidomycosis, is an infection caused by the fungus Coccidioides. The fungus is known to live in the soil in the southwestern United States and parts of Mexico and Central and South America. The fungus was also recently found in south-central Washington. People can get Valley fever by breathing in the microscopic fungal spores from the air, although most people who breathe in the spores don’t get sick. Usually, people who get sick with Valley fever will get better on their own within weeks to months, but some people will need antifungal medication. Certain groups of people are at higher risk for becoming severely ill. It’s difficult to prevent exposure to Coccidioides in areas where it’s common in the environment, but people who are at higher risk for severe Valley fever should try to avoid breathing in large amounts of dust if they’re in these areas.

Wikipedia : 77 Coccidioidomycosis (/kɒkˌsɪdiɔɪdoʊmaɪˈkoʊsɪs/, kok-sid-ee-oy-doh-my-KOH-sis), commonly known as... more...

Related Diseases for Coccidioidomycosis

Diseases related to Coccidioidomycosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 223)
# Related Disease Score Top Affiliating Genes
1 cryptococcosis 30.4 CARD9 MBL2
2 q fever 30.1 IL10 TLR4
3 brucellosis 30.1 IL10 TLR4
4 pneumonia 30.0 IL10 MBL2 TLR4
5 prosthetic joint infection 30.0 MBL2 TLR4
6 leishmaniasis 29.7 IFNGR1 IL10 TLR4
7 lepromatous leprosy 29.6 IFNGR1 IL10
8 paracoccidioidomycosis 29.5 IL10 TLR4
9 lymphadenitis 29.4 IFNGR1 IL10 TLR4
10 pulmonary tuberculosis 29.3 IFNGR1 IL10 MBL2
11 systemic lupus erythematosus 29.1 IL10 MBL2 STAT1 TLR4
12 candidiasis 28.4 CARD9 CLEC7A IL10 MBL2 STAT1
13 rift valley fever 13.0
14 coccidiosis 12.7
15 cryptosporidiosis 11.4
16 toxoplasmosis 11.4
17 sarcocystosis 11.4
18 cyclosporiasis 11.1
19 cystoisosporiasis 11.1
20 histoplasmosis 10.5
21 encephalitis 10.4
22 blastomycosis 10.4
23 campylobacteriosis 10.3 STAT1 TLR4
24 neisseria meningitidis infection 10.2 MBL2 TLR4
25 fungal keratitis 10.2 CLEC7A TLR4
26 crimean-congo hemorrhagic fever 10.2
27 osteomyelitis 10.2
28 diarrhea 10.2
29 west nile virus 10.2
30 bacterial vaginosis 10.2 MBL2 TLR4
31 vulvovaginal candidiasis 10.2 CLEC7A MBL2
32 typhoid fever 10.2 IFNGR1 TLR4
33 acquired immunodeficiency syndrome 10.2
34 meningitis 10.2
35 immunodeficiency 17 10.2 CARD9 STAT1
36 phaeohyphomycosis 10.1 CARD9 STAT1
37 candidiasis, familial, 2 10.1 CARD9 CLEC7A
38 chikungunya 10.1
39 yellow fever 10.1
40 subcutaneous mycosis 10.1 CARD9 CLEC7A
41 chromoblastomycosis 10.1 CARD9 CLEC7A
42 salmonellosis 10.1 IFNGR1 STAT1 TLR4
43 intussusception 10.1
44 malaria 10.1
45 lymphoma 10.1
46 plague 10.1
47 pneumothorax 10.0
48 pericarditis 10.0
49 dermatitis 10.0
50 pouchitis 10.0 IL10 TLR4

Graphical network of the top 20 diseases related to Coccidioidomycosis:



Diseases related to Coccidioidomycosis

Symptoms & Phenotypes for Coccidioidomycosis

Symptoms:

12
  • arthritis
  • chest pain
  • conjunctivitis

UMLS symptoms related to Coccidioidomycosis:


fever, pruritus

GenomeRNAi Phenotypes related to Coccidioidomycosis according to GeneCards Suite gene sharing:

27 (show all 49)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.42 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.42 CLEC7A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.42 CLEC7A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.42 CLEC7A MBL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.42 IL10 TLR4 IFNGR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.42 TLR4 MBL2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.42 CARD9
8 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.42 CLEC7A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.42 CARD9
10 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.42 IL10 IFNGR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.42 CLEC7A IL10 TLR4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.42 IFNGR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.42 IL10 IFNGR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.42 CLEC7A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.42 CARD9
16 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.42 CLEC7A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.42 CLEC7A CYP51A1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.42 CLEC7A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.42 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.42 CLEC7A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.42 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.42 CLEC7A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.42 TLR4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.42 CARD9
25 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.42 CLEC7A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.42 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.42 CLEC7A MBL2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.42 CLEC7A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.42 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.42 CLEC7A IL10 CARD9 CYP51A1 MBL2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.42 CYP51A1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.42 IL10 CARD9
33 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.42 CLEC7A
34 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.42 CLEC7A
35 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.42 CARD9
36 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.42 IFNGR1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.42 CARD9 MBL2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.42 IFNGR1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.42 IL10 MBL2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.42 IFNGR1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.42 CYP51A1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.42 CLEC7A
43 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.42 IL10
44 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.42 IL10
45 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.42 CLEC7A
46 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.42 IL10
47 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.42 IL10
48 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.42 IL10
49 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.42 CLEC7A CYP51A1

MGI Mouse Phenotypes related to Coccidioidomycosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.73 CLEC7A CYP51A1 IFNGR1 IL10 STAT1 TLR4
2 hematopoietic system MP:0005397 9.7 CARD9 CLEC7A IFNGR1 IL10 MBL2 STAT1
3 homeostasis/metabolism MP:0005376 9.56 CARD9 CLEC7A CYP51A1 IFNGR1 IL10 MBL2
4 immune system MP:0005387 9.23 CARD9 CLEC7A CYP51A1 IFNGR1 IL10 MBL2

Drugs & Therapeutics for Coccidioidomycosis

Drugs for Coccidioidomycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
3
Spiramycin Approved Phase 4,Phase 3,Phase 1,Not Applicable 24916-50-5
4
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-14-0 4993
5
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
6
Sulfadiazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 68-35-9 5215
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
8
Fluconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 86386-73-4 3365
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
10
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable 7440-70-2 271
11 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
12 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
13 Central Nervous System Depressants Phase 4
14 Neurotransmitter Agents Phase 4,Phase 2
15 Antimanic Agents Phase 4
16 Psychotropic Drugs Phase 4,Phase 2
17 Tranquilizing Agents Phase 4
18 Anticonvulsants Phase 4
19 GABA Agents Phase 4
20 Trace Elements Phase 4,Phase 1
21 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antidotes Phase 4,Phase 2,Phase 1,Not Applicable
24 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Bone Density Conservation Agents Phase 4,Phase 1
27 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Nutrients Phase 4,Phase 1
30 Hormones Phase 4,Phase 3,Phase 1,Not Applicable
31 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
32 Vitamins Phase 4,Phase 1
33 Calcium, Dietary Phase 4,Phase 2,Phase 1,Not Applicable
34 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Micronutrients Phase 4,Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Not Applicable
37 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 1,Not Applicable
38 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 1,Not Applicable
39 Steroid Synthesis Inhibitors Phase 4,Phase 3,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Not Applicable
41 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43
Nitazoxanide Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 55981-09-4 41684
44
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
45
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
46
Ritonavir Approved, Investigational Phase 3,Phase 2,Phase 1 155213-67-5 392622
47
Sulfamethoxazole Approved Phase 3 723-46-6 5329
48
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
49
protease inhibitors Phase 3,Phase 2,Phase 1
50 Atazanavir Sulfate Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia Completed NCT02011750 Phase 4 Sodium Valproate treatment;Placebo
2 Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis Recruiting NCT00004317 Phase 4 Leucovorin calcium;Pyrimethamine;Spiramycin;Sulfadiazine
3 Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) Terminated NCT02663674 Phase 4 Fluconazole
4 Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis Unknown status NCT01202500 Phase 3
5 POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) Completed NCT00423267 Phase 3 Posaconazole;Fluconazole
6 A Multi-center Study of Spherule-Derived Coccidioidin Completed NCT00690092 Phase 3
7 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
8 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules
9 Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy Completed NCT01189448 Phase 3 Pyrimethamine/Sulfadiazine;Spiramycine
10 Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis Completed NCT01449877 Phase 3 Trimethoprim-Sulfamethoxazole
11 Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Terminated NCT00004986 Phase 3 Nitazoxanide
12 Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine Completed NCT00415051 Phase 2
13 Safety and Immunogenicity Study of Rift Valley Fever Vaccine Completed NCT00584194 Phase 2
14 Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Completed NCT00289185 Phase 2
15 Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children Completed NCT00307021 Phase 2
16 Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children Completed NCT00055107 Phase 1, Phase 2 Nitazoxanide
17 A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium Completed NCT00001081 Phase 2 Nitazoxanide
18 Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis Completed NCT00000794 Phase 2 Sulfadiazine;Clarithromycin;Atovaquone;Pyrimethamine;Leucovorin calcium
19 A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 Completed NCT00000771 Phase 2 Paromomycin sulfate
20 Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients Completed NCT00000643 Phase 2 Pyrimethamine;Leucovorin calcium
21 Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine Recruiting NCT03609398 Phase 2
22 A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Recruiting NCT03341767 Phase 2 Clofazimine;Placebo
23 Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated Enrolling by invitation NCT00869713 Phase 2
24 Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment Terminated NCT00614666 Phase 1, Phase 2 nikkomycin Z
25 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
26 Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients Terminated NCT00057486 Phase 1, Phase 2 IL-12
27 Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Withdrawn NCT02908334 Phase 2 Sertraline
28 Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects Completed NCT03258762 Phase 1 Pyrimethamine;Calcium folinate
29 Antiretroviral Drug Interaction Study in Volunteers With HIV Completed NCT01479361 Phase 1 Atovaquone 750 mg twice daily;Atovaquone 1500 mg twice daily
30 A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients Completed NCT00002248 Phase 1 Cryptosporidium Immune Whey Protein Concentrate (Bovine)
31 A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea Completed NCT00001018 Phase 1 Letrazuril
32 A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea Completed NCT00000980 Phase 1 Spiramycin
33 A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients Completed NCT00000973 Phase 1 Pyrimethamine;Leucovorin calcium;Zidovudine
34 A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS Completed NCT00000966 Phase 1 Azithromycin;Pyrimethamine;Leucovorin calcium
35 A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis Unknown status NCT00002158 Not Applicable Nitazoxanide
36 Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis Completed NCT00796809
37 Rift Valley Fever in Kenya Completed NCT00287014
38 A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common Completed NCT00002325 Not Applicable Fluconazole
39 Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis Completed NCT00002010 Not Applicable Fluconazole
40 HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University Completed NCT01339416
41 Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis Completed NCT00322439 Etanercept
42 Immunoblotting and Goldmann-Witmer Coefficient for Ocular Toxoplasmosis Completed NCT03948750
43 Cerebral Toxoplasmosis and AIDS Completed NCT00803621
44 Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis Completed NCT02843438 Not Applicable Anti-toxoplasmosis treatment;Anti-inflammatory treatments
45 Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events Completed NCT01699841
46 Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya Completed NCT01695304 Not Applicable
47 Transmission and the Respiratory Tract in Cryptosporidiosis Completed NCT00507871
48 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Completed NCT00645697
49 Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs Completed NCT00002328 Not Applicable Azithromycin
50 A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS Completed NCT00002278 Not Applicable Diclazuril

Search NIH Clinical Center for Coccidioidomycosis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: coccidioidomycosis

Genetic Tests for Coccidioidomycosis

Anatomical Context for Coccidioidomycosis

MalaCards organs/tissues related to Coccidioidomycosis:

42
Testes, Skin, Lung, Prostate, Liver, Bone, Brain

Publications for Coccidioidomycosis

Articles related to Coccidioidomycosis:

(show top 50) (show all 2757)
# Title Authors Year
1
Pediatric Coccidioidomycosis: Case Series From a California Pediatric Infectious Diseases Clinic. ( 29620721 )
2019
2
Coccidioidomycosis in selected immunosuppressed hosts. ( 29669037 )
2019
3
The Utility of Screening for Coccidioidomycosis in Recipients of Inhibitors of Tumor Necrosis Factor α. ( 30084971 )
2019
4
Interlaboratory agreement of coccidioidomycosis enzyme immunoassay from two different manufacturers. ( 30085141 )
2019
5
Cutaneous effects associated with fluconazole in patients treated for coccidioidomycosis. ( 30229876 )
2019
6
A novel form of intracranial coccidioidomycosis is present in dogs and exhibits characteristic clinical and magnetic resonance imaging findings. ( 30260537 )
2019
7
Corticosteroids in the Management of Severe Coccidioidomycosis. ( 30290191 )
2019
8
Novel canine anti-Coccidioides immunoglobulin G enzyme immunoassay aids in diagnosis of coccidioidomycosis in dogs. ( 30649403 )
2019
9
Occupational coccidioidomycosis surveillance and recent outbreaks in California. ( 30690596 )
2019
10
Coccidioidomycosis in Latin America. ( 30690597 )
2019
11
Epidemiology of coccidioidomycosis among children in California, 2000-2016. ( 30690598 )
2019
12
Update on the Epidemiology of coccidioidomycosis in the United States. ( 30690599 )
2019
13
Selected Clinical Features of Coccidioidomycosis in Dogs. ( 30690600 )
2019
14
Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis. ( 30690601 )
2019
15
A review of innate and adaptive immunity to coccidioidomycosis. ( 30690602 )
2019
16
Coccidioidomycosis: What a long strange trip it's been. ( 30690606 )
2019
17
Clinical features of cats diagnosed with coccidioidomycosis in Arizona, 2004-2018. ( 30784342 )
2019
18
Utility of Whole-Genome Sequencing to Ascertain Locally Acquired Cases of Coccidioidomycosis, Washington, USA. ( 30789132 )
2019
19
De Novo Coccidioidomycosis Among Solid Organ Transplant Recipients 1 or More Years After Transplant. ( 30811848 )
2019
20
Coccidioidomycosis Among American Indians and Alaska Natives, 2001-2014. ( 30882015 )
2019
21
Optical Coherence Tomography Angiography Highlights Chorioretinal Lesions in Ocular Coccidioidomycosis. ( 30893459 )
2019
22
The mysterious desert dwellers: Coccidioides immitis and Coccidioides posadasii, causative fungal agents of coccidioidomycosis. ( 30898028 )
2019
23
Coccidioidomycosis with emperipolesis in fine needle aspiration. ( 30908749 )
2019
24
The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California. ( 30925716 )
2019
25
Notes from the Field: Multistate Coccidioidomycosis Outbreak in U.S. Residents Returning from Community Service Trips to Baja California, Mexico - July-August 2018. ( 30973851 )
2019
26
Management of asymptomatic coccidioidomycosis in patients with rheumatic diseases. ( 31065743 )
2019
27
Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats. ( 30396029 )
2019
28
Rift Valley Fever: An Ancient Plague on Its Way Out of Africa? ( 30722759 )
2019
29
Development of a Quantitative RT-PCR Assay to Differentiate Rift Valley Fever Virus Smithburn Vaccine Strain from Clone 13 Vaccine Strain. ( 30300113 )
2019
30
Lesions and Cellular Tropism of Natural Rift Valley Fever Virus Infection in Adult Sheep. ( 30343650 )
2019
31
Seroprevalence of Rift Valley fever virus in cattle in the Democratic Republic of the Congo. ( 30350160 )
2019
32
First occurrence of Rift Valley fever outbreak in Niger, 2016. ( 30411868 )
2019
33
Molecular aspects of Rift Valley fever virus and the emergence of reassortants. ( 30426314 )
2019
34
Rift Valley fever: An open-source transmission dynamics simulation model. ( 30625221 )
2019
35
Rift Valley Fever Reemergence after 7 Years of Quiescence, South Africa, May 2018. ( 30666946 )
2019
36
First Laboratory-Confirmed Outbreak of Human and Animal Rift Valley Fever Virus in Uganda in 48 Years. ( 30675833 )
2019
37
Rift Valley Fever Viral RNA Detection by In Situ Hybridization in Formalin-Fixed, Paraffin-Embedded Tissues. ( 30720389 )
2019
38
The One Health Approach is Necessary for the Control of Rift Valley Fever Infections in Egypt: A Comprehensive Review. ( 30736362 )
2019
39
Rift Valley Fever Virus Exposure amongst Farmers, Farm Workers, and Veterinary Professionals in Central South Africa. ( 30736488 )
2019
40
Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves. ( 30773401 )
2019
41
Tracking Rift Valley fever: From Mali to Europe and other countries, 2016. ( 30808441 )
2019
42
Identification and evaluation of antivirals for Rift Valley fever virus. ( 30827375 )
2019
43
Individual-based network model for Rift Valley fever in Kabale District, Uganda. ( 30835724 )
2019
44
Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania. ( 30843406 )
2019
45
Rift Valley Fever Virus and Yellow Fever Virus in Urine: A Potential Source of Infection. ( 30888606 )
2019
46
The influence of raw milk exposures on Rift Valley fever virus transmission. ( 30893298 )
2019
47
A comparative genome analysis of Rift Valley Fever virus isolates from foci of the disease outbreak in South Africa in 2008-2010. ( 30897082 )
2019
48
Evaluation of a Virus Neutralisation Test for Detection of Rift Valley Fever Antibodies in Suid Sera. ( 30934604 )
2019
49
Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. ( 30936489 )
2019
50
A multiplex fluorescence microsphere immunoassay for increased understanding of Rift Valley fever immune responses in ruminants in Kenya. ( 30974177 )
2019

Variations for Coccidioidomycosis

Expression for Coccidioidomycosis

Search GEO for disease gene expression data for Coccidioidomycosis.

Pathways for Coccidioidomycosis

Pathways related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 CARD9 CLEC7A IFNGR1 IL10 MBL2 STAT1
2
Show member pathways
12.37 CARD9 IFNGR1 IL10 MBL2 STAT1 TLR4
3 12.27 CARD9 IL10 STAT1
4
Show member pathways
12.21 IFNGR1 IL10 STAT1 TLR4
5
Show member pathways
12.1 IFNGR1 IL10 STAT1
6
Show member pathways
12.02 IFNGR1 STAT1 TLR4
7
Show member pathways
11.91 IFNGR1 STAT1 TLR4
8
Show member pathways
11.89 IFNGR1 IL10 STAT1 TLR4
9
Show member pathways
11.87 IFNGR1 STAT1 TLR4
10 11.85 IFNGR1 STAT1 TLR4
11
Show member pathways
11.8 CARD9 CLEC7A IL10 STAT1
12 11.79 CLEC7A MBL2 TLR4
13
Show member pathways
11.57 IFNGR1 IL10 STAT1 TLR4
14 11.52 IFNGR1 IL10 STAT1
15 11.42 IL10 MBL2
16 11.35 CARD9 CLEC7A IFNGR1 IL10 STAT1 TLR4
17 11.26 IL10 TLR4
18 11.1 IFNGR1 STAT1
19 11.07 IL10 TLR4

GO Terms for Coccidioidomycosis

Biological processes related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.78 CARD9 CLEC7A MBL2 TLR4
2 response to drug GO:0042493 9.73 CARD9 IL10 STAT1
3 cytokine-mediated signaling pathway GO:0019221 9.72 IFNGR1 IL10 STAT1
4 innate immune response GO:0045087 9.71 CARD9 CLEC7A MBL2 TLR4
5 defense response to bacterium GO:0042742 9.7 IL10 MBL2 TLR4
6 positive regulation of interleukin-6 production GO:0032755 9.58 CARD9 TLR4
7 positive regulation of tumor necrosis factor production GO:0032760 9.57 CARD9 TLR4
8 negative regulation of tumor necrosis factor production GO:0032720 9.54 IL10 TLR4
9 negative regulation of interferon-gamma production GO:0032689 9.51 IL10 TLR4
10 negative regulation of interleukin-6 production GO:0032715 9.49 IL10 TLR4
11 defense response to protozoan GO:0042832 9.46 CLEC7A IL10
12 positive regulation of stress-activated MAPK cascade GO:0032874 9.43 CARD9 TLR4
13 positive regulation of macrophage activation GO:0043032 9.37 IL10 TLR4
14 negative regulation of growth of symbiont in host GO:0044130 9.32 IL10 MBL2
15 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.26 STAT1 TLR4
16 positive regulation of interferon-alpha production GO:0032727 9.16 STAT1 TLR4
17 regulation of interferon-gamma-mediated signaling pathway GO:0060334 8.96 IFNGR1 STAT1
18 positive regulation of MHC class II biosynthetic process GO:0045348 8.62 IL10 TLR4

Sources for Coccidioidomycosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....